| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/12/2023 | 591.49% | Alliance Global Partners | → $6.5 | Reiterates | → Buy |
| 04/18/2022 | -36.17% | Noble Capital Markets | → $0.6 | Initiates Coverage On | → Outperform |
| 04/18/2019 | — | Roth Capital | Upgrades | Neutral → Buy | |
| 07/27/2018 | — | B. Riley Securities | Downgrades | Buy → Neutral | |
| 07/27/2018 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 06/06/2018 | 751.06% | B. Riley Securities | → $8 | Initiates Coverage On | → Buy |
What is the target price for Tonix Pharmaceuticals (TNXP)?
The latest price target for Tonix Pharmaceuticals (NASDAQ: TNXP) was reported by Alliance Global Partners on January 12, 2023. The analyst firm set a price target for $6.50 expecting TNXP to rise to within 12 months (a possible 591.49% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tonix Pharmaceuticals (TNXP)?
The latest analyst rating for Tonix Pharmaceuticals (NASDAQ: TNXP) was provided by Alliance Global Partners, and Tonix Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Tonix Pharmaceuticals (TNXP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tonix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tonix Pharmaceuticals was filed on January 12, 2023 so you should expect the next rating to be made available sometime around January 12, 2024.
Is the Analyst Rating Tonix Pharmaceuticals (TNXP) correct?
While ratings are subjective and will change, the latest Tonix Pharmaceuticals (TNXP) rating was a reiterated with a price target of $0.00 to $6.50. The current price Tonix Pharmaceuticals (TNXP) is trading at is $0.94, which is within the analyst's predicted range.